Educational Autumn Meeting 2008
on
Advances in Cardiovascular Drug Therapy

Cardiovascular protection
by cardiovascular drug therapy

This meeting is sponsored through an unrestricted educational grant provided by Takeda Pharmaceuticals Europe Ltd

Venue: Vienna, AT, Vienna Hilton Hotel
Date: Saturday 29 – Sunday 30, November 2008

Session 1: Saturday 15:00 – 17:00
Session 2: Saturday 17:30 – 19:00
Session 3: Sunday 08:30 – 10:00
Session 4: Sunday 10:30 – 12:00

Address for correspondence:

Dr Kurt Stoschitzky, FESC
Working Group on Cardiovascular Pharmacology and Drug Therapy
of the European Society of Cardiology
Universitätsklinik für Innere Medizin
Abteilung für Kardiologie
Auenbruggerplatz 15
A-8036 Graz, Austria
Phone: +43-316-385-80261
Fax: +43-316-385-3733
e-mail: kurt.stoschitzky@meduni-graz.at
Programme

Saturday, November 29, 2008

15:00 – 17:00: **Introduction to the field**

**Chair:** Faiez Zannad (Nancy, FR), Kurt Stoschitzky (Graz, AT)

15:00 – 16:00: Zeljko Reiner (Zagreb, HR)  
*Cardiovascular prevention under the burden of cardiovascular diseases: What should be done and what can be done?*

16:00 – 16:30: Ferenc Follath (Zürich, CH)  
*Ethical considerations of cardiovascular risk reduction*

16:30 – 17:00: Stevo Julius (Ann Arbor, MI)  
*Clinical trials in arterial hypertension – the past and the future*

17:00 – 18:00: **Coffee break**

18:00 – 19:00: **Treatment of hyperlipidaemia**

**Chair:** Dan Atar (Oslo, NO), Keld Kjeldsen (Kobenhavn, DK)

18:00 – 19:00: Heinz Drexel (Feldkirch, AT)  
*Statins, Fibrates, Nicotinic acid, Cholesterol absorption inhibitors, Anion-exchange resins, Omega-3 fatty acids – which drugs for which patients?*

19:30: **Extraordinary Nucleus Meeting**  
Working Group on Cardiovascular Pharmacology and Drug Therapy
Sunday, November 30, 2008

8:30 – 10:00:  
**Treatment of arterial hypertension**  
*(Focus on candesartan)*

8:30 – 10:00: **Chair:**  
Wiek van Gilst (Groningen, NL), Stefan Agewall (Stockholm, SE)

8:30 – 9:00: Roland Asmar (Paris, FR)  
*Blood-pressure control and beyond – are all ARBs equal?*

9:00 – 9:30: Ulrike Steckelings (Berlin, DE)  
The evolving story of the RAAS in hypertension, diabetes and CV disease – moving from macrovascular to microvascular targets

9:30 – 10:00: Massimo Porta (Torino, IT)  
The future of managing microvascular complications in diabetes – what does DIRECT tell us?

10:00 – 10:30:  **Coffee break**

10:30 – 12:00  
**Treatment of diabetes mellitus**  
*(Focus on pioglitazone)*

10:30 – 12:00: **Chair:**  
Maria Angeles Alonso Garcia (Madrid, ES), Franco Naccarella (Bologna, IT), Brian Prichard (London, UK)

10:30 – 11:00: Jochen Seufert (Freiburg, DE)  
*Glycaemic durability and control in Type 2 Diabetes: recent insights*

11:00 – 11:30: Bruno Vergès (Dijon, FR)  
*Lipid modification in diabetes: The role of LDL and HDL*

11:30 – 12:00: D John Betteridge (London, UK)  
**CHICAGO, PERISCOPE and PROactive:**  
*CV risk modification in diabetes with pioglitazone*
Get actively involved…

... and become a member of the

ESC Working Group on Cardiovascular Pharmacology & Drug Therapy

and contribute to research and education in your area of expertise:

- Network and exchange knowledge with your peers
- Help to define strategies for treatment in your sector
- Contribute to and benefit from educational activities
- Stay abreast of advances and developments in your field

Apply for membership, and enjoy exclusive advantages:

- Regular informations on the Working Group’s activities and meetings
- Discount prices on the ESC Educational Products
- Exclusive subscription rates for all ESC Journals (including the European Heart Journal)
- A free set of the latest ESC Pocket Guidelines on the occasion of each year’s ESC Annual Congress

Get more informations and your online application form at www.escardio.org/pharmacology